Samsung Biologics – World Class Benchmarking
Company: Samsung Biologics Company Limited
Bloomberg ticker: 207940 KS
Market cap: US$3,051m
Background: Samsung Biologics Company Limited is a contract manufacturer and developer of biopharmaceutical products–drugs made from biological sources. The company currently has four production plants, with a fifth scheduled to open in 2025. Clients include leading global companies like Pfizer, GlaxoSmithKline, Eli Lilly, and AstraZeneca.
World Class Benchmarking of Samsung Biologics
- Profitable Growth rank of 4 was up compared to the prior period’s 5th rank
- This is above average performance compared to 360 large Health Care companies worldwide
- Profitability rank of 4 was the same as its Growth rank of 4
- Profitability rank of 4 was up compared to the prior period’s 5th rank
- This is above average performance compared to peers
- Growth rank of 4 was up compared to the prior period’s 5th rank
- This is above average performance compared to peers
DISCLAIMER: This content is for information purposes only. It is not intended to be investment advice. Readers should not consider statements made by the author(s) as formal recommendations and should consult their financial advisor before making any investment decisions. While the information provided is believed to be accurate, it may include errors or inaccuracies. The author(s) cannot be held liable for any actions taken as a result of reading this article.